Results 21 to 30 of about 961,470 (198)
Molecular Therapy, 2020 Chimeric antigen receptor T-cell（CAR-T）therapy has revolutionized the clinical treatment of hematological malignancies due to the prominent anti-tumor effects.
Xue Li +22 more
semanticscholar +1 more source
Pleomorphic plasma cell leukemia [PDF]
Blood, 2015 ![Figure][1] This peripheral blood smear is from a 72-year-old woman, taken several hours before she died of recurrent plasma cell myeloma and newly developed secondary plasma cell leukemia.
Huifei, Liu, Xiaoping, Sun
openaire +2 more sources
Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases
Hematology/Oncology and Stem Cell Therapy, 2015 Plasma cell leukemia (PCL) is a rare hematologic malignancy with very poor outcome. It is defined by the presence of >2 × 109/L plasma cells or >20%s plasmacytosis of the differential white cell count in the peripheral blood.
Nahlah Alghasham +3 more
doaj +1 more source
Hematology, 2023 Background Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, exhibiting a more unfavorable prognosis than multiple myeloma. PCL is classified into pPCL and sPCL.
Jiaheng Guan, Jinlong Ma, Baoan Chen
doaj +1 more source
Primary plasma cell leukemia and autologous stem cell transplantation
Haematologica, 2010 Background Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple myeloma, with a median survival of 8–12 months. The results of conventional therapy are
Mary B. Drake +7 more
doaj +1 more source
Hairy Cell Leukemia with Marrow Reactive Plasmacytosis and Mast Cell Hyperplasia: A Case Report and Brief Review of the Literature [PDF]
Journal of Kerman University of Medical Sciences, 2023 Hairy cell leukemia (HCL) and HCL-like disorders, including HCL-variant, are disorders of heterogeneous mature lymphoid B-cells known for their hairy cell infiltration accompanied by a specific genetic profile, various clinical presentations, and, as ...
Elham Jafari +2 more
doaj +1 more source
B-lymphoblastic leukemia/lymphoma arising in treated plasma cell myeloma: A rare second malignancy
Human Pathology: Case Reports, 2017 Plasma cell myeloma (PCM) is a neoplasm of plasma cells, end-stage post germinal center B cells, which shows a variable clinical spectrum from asymptomatic to aggressive; the nature of the disease is generally progressive. Rarely, leukemia arises treated
D. Kurant +3 more
doaj +1 more source
Plasma cell leukemia: A case series from South India with emphasis on rarer variants
Indian Journal of Medical and Paediatric Oncology, 2014 Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell dyscrasia. They occur de novo (primary) or as a late manifestation of multiple myeloma (secondary). Patients present with anemia, thrombocytopenia, renal failure, organomegaly and
G Rajeswari +6 more
doaj +1 more source
Frontiers in Oncology, 2020 Plasma cell dyscrasias and myeloproliferative neoplasms (MPN) are hematologic malignancies arising from two distinct hematopoietic cell lineages. They rarely occur concomitantly. Here, we report a case of a patient with a recent diagnosis of a JAK2 V617F
Christine J. Kurian +4 more
doaj +1 more source
Journal of Applied Hematology, 2015 Plasma cell leukemia (PCL) is defined by the presence of more than 2 × 109/L PCs in the peripheral blood. It is a very rare type of leukemia with poor outcome. In this case, we report a PCL case with peripheral blood morphology of hairy cell leukemia. We
Nahlah Alghasham +3 more
doaj +1 more source